AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05155371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titration of Optimal Positive End-expiratory Pressure
Description: Titration of Optimal Positive End-expiratory Pressure with two different methods
Study NCT05473208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton
Description: Lumbar assistive exoskeleton evaluation
Study NCT02669797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-home Visits and Food Preparation Activities
Description: Families will participate in eight in-home education activities. The visits will focus on family meal quality (dietary, interpersonal) and quantity (meal frequency) factors found in prior studies to be associated with child weight and weight-related behaviors. Eight of the visits (every other week) will be delivered by a CHW and will last 90 minutes. Additionally ,a family meal food preparation activity will occur to help support families in learning skills to increase family meal quality and quantity. On weeks opposite of the in-home education visits with a CHW, families will be given a Try it Yourself activity to reinforce the messages (e.g., use family meals as a family connection time) and skills (e.g., recipe that requires families to steam vegetables) taught by the CHW during the in-home education visits.
Study NCT02669797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention
Description: Parents will receive daily EMI messages regarding suggestions for increasing meal quality/quantity via a smartphone application, based on the stress level and source of stress they reported earlier in the day. Specifically, parents will receive two push notifications in the morning to report their stress level and type/source of stress (e.g., work, children, finances). Then, based on the reported stress level and source of stress, parents will be texted tips/ideas for carrying out a nutritionally and emotionally healthful family meal the same night, in the face of stress. If parents report no stress on their EMI measure earlier in the day, they will be provided with a menu of options regarding what type of meal tip they would prefer later in the day (e.g., recipe ideas, meal prep tips, mealtime conversation starters. Parents will be able to respond to the EMI messages indicating preferred tips so that EMI tips become more meaningful/relevant to the needs of each family.
Study NCT02669797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on Video-recorded Family Meals
Description: Parents will video-record and upload via their cellphone one family meal every other week, which will be watched by intervention staff. Using Motivational Interviewing, CHWs will give specific feedback on how to adapt negative mealtime behaviors and provide reinforcement for positive behaviors seen in the videos, based on a validated interpersonal coding tool called the Iowa Family Interaction Rating Scales (IFIRS). Additionally, feedback will be given on the dietary healthfulness of the meal, based on a validated coding tool called the Healthfulness of Meal Index (HOM). After feedback, family members will be taught specific skills to improve their family meal processes and behaviors that vary from food preparation skills, to increasing healthful food options at meals, or role-playing family interactions to improve the emotional atmosphere at the meal. Families will also set SMART goals at each visit regarding family meal quality and quantity.
Study NCT02669797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance
Description: After 16 weeks, EMI family meal tips for all arms will be reduced to only the days in which parent's report their highest stress levels. Stress profiles will be created for each parent in order to tailor the EMI family meals tips to days in which they experience their highest levels of stress. For example, during the 16-weeks of EMI, a parent may report their highest stress levels on Tuesdays and Thursdays. The stress profile that would be created for the parent during the maintenance phase would include receiving text messages only on Tuesdays and Thursdays. The parent would then receive these EMI family meal tips only on Tuesdays and Thursdays throughout the 8-week maintenance phase..
Study NCT05218850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butyrate
Description: Butyrate enemas will be administered once a day for 12 weeks
Study NCT04997889 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Artificial salivary containing cumin and ginger extract
Description: The artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the artificial salivary containing cumin and ginger extract will be stopped for 7-10 days. After that, the artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 3 days.
Study NCT06476327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: experimental 1 group
Description: A camera is installed on the walker used in the training, and the recorded video is mirrored in real-time to a tablet computer. Participants can view this video through smart glasses connected to the tablet computer. A glasses strap will be used to secure the glasses, ensuring there is no interference with walking.~Participants will undergo a total of 20 training sessions, five times a week for four weeks, with each session lasting 30 minutes. Participants will have a 4-minute break during the 30-minute gait training session.~Participants will be given a period to adapt to wearing the robot, and after that, the intervention will be conducted based on each participant's individual abilities and adaptation.
Study NCT04997889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercial artificial salivary
Description: The commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the commercial artificial salivary will be stopped for 7-10 days. After that, the commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 3 days.
Study NCT06476327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: experimental 2 group
Description: Participants will undergo a total of 20 training sessions, five times a week for four weeks, with each session lasting 30 minutes. Participants will have a 4-minute break during the 30-minute gait training session.~Participants will be given a period to adapt to wearing the robot, and after that, the intervention will be conducted based on each participant's individual abilities and adaptation.
Study NCT06430047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EsoDuo® Tablet
Description: QD, PO
Study NCT05339438 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: functional MRI
Description: Functional MRI scanning (around 1h30 min): SMS + multi-band (with FPVS paradigms for both)
Study NCT04645017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intergenerational Music Program
Description: Music activities will be lead by adolescent musicians for older adult participants.
Study NCT04718181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risdiplam
Description: Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.
Study NCT04718181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: Omeprazole will be administered orally as a capsule at a dose of 40 mg per day
Study NCT05813327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG20
Description: ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m\^2 via intramuscular injection into either the deltoid or gluteal muscle.
Study NCT05813327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide will be administered intravenously per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
Study NCT05813327 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will begin on C2D1 and will continue as per institutional practice.
Study NCT05813327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna will be administered for supportive care either intravenously or by mouth per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
Study NCT06012487 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Low BPV Regimen
Description: Each the patients' physician will invite patients to complete a 48-hour ABPM, then undergo cross-titration from their current antihypertensive regimen to a low BPV regimen, consisting of Amlodipine and Indapamide. Study staff will suggest to the treating physician to initially start patients on Amlodipine 5mg daily, with uptitration to 10mg daily to a goal systolic blood pressure (SBP)\<130 mmHg. Indapamide will be suggested to be added at 1.25mg daily and increased to 2.5mg daily, as needed to meet target SBP. Other antihypertensive medications will be suggested to be discontinued as the SBP target is reached. Patients not meeting target SBP on maximally tolerated Amlodipine and Indapamide will be suggested to have a long acting angiotensin-converting enzyme (ACE)/ angiotensin receptor blocker (ARB) added to their therapy. Patients will complete another 48-hour ABPM after 1 week at target SBP on the low-BPV regimen.
Study NCT04879628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441344 IV
Description: Pharmaceutical form: Solution Route of administration: IV infusion
Study NCT04879628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo IV
Description: Pharmaceutical form: Solution Route of administration: IV infusion
Study NCT04879628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441344 SC
Description: Pharmaceutical form: Solution Route of administration: SC injection
Study NCT04879628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo SC
Description: Pharmaceutical form: Solution Route of administration: SC injection
Study NCT04879628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MRI contrast-enhancing preparations
Description: gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem
Study NCT04879628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRI contrast-enhancing preparations
Description: gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem
Study NCT03395392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-101
Description: NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
Study NCT03395392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurasidone HCl
Description: Lurasidone HCl will be given twice a day by mouth
Study NCT05446896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AR guidance with Hololens 2
Description: The AR instructions were developed as a step-by-step guide with the same text and images as in the printed manual, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
Study NCT06416852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Alfatide Injection
Description: A single dose of (0.1\~0.15）±0.015 mCi/kg IV injection of 18F-Alfatide. The patients will be intravenously injected with 18F-Alfatide Injection and undergo PET/CT scan at 60 min±10 min after the injection.
Study NCT06416852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG Injection
Description: A single dose of 5～10mCi IV injection of 18F-FDG. The patients will be intravenously injected with 18F-FDG Injection and undergo PET/CT scan at 40 min±10 min after the injection.
Study NCT05123196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554
Description: Oral Capsule
Study NCT05123196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study NCT05024123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 \~ 180 min to measure 1) nitrate and 2) cGMP content.
Study NCT05024123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AstraGin
Description: Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 \~ 180 min to measure 1) nitrate and 2) cGMP content.
Study NCT05862324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAC01-CLDN18.2
Description: TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel.
Study NCT05238467 — intervention group
Intervention type: OTHER
Intervention: COVID antibody titers in the blood
Description: COVID antibody titers will be quantitatively assessed at baseline, 8 weeks and approximately 6, 9, and 12 months from date of study enrollment. Titers will be compared to levels in 25 age matched adult participants with no prior history of cancer or prior history of non-metastatic solid cancer invasive cancer treated with a curative intent,.and in 25 age matched cancer participants who are on non-immunosuppressive treatments as defined below.
Study NCT04304755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid 5 MG in 5 ML Injection
Description: Zoledronic acid
Study NCT04304755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: NaCl 0.9%
Study NCT06403228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Structured Nursing Interventions
Description: In the study, 8 days of mindfulness-based structured nursing interventions were applied to high-risk pregnant women. The program lasts 60 minutes each day. The program includes short body scanning meditation, breath awareness meditation, sitting meditation, compassion meditation.
Study NCT05763095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention for Emotional Distress
Description: Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
Study NCT06372301 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography
Description: Patients will be investigated with dobutamine stress echocardiography (increasing doses of dobutamine infusion and simulatneous echocardiogarphic evaluation) to assess aortic valve area and projected aortic valve area.
Study NCT05992181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEORTHO
Description: early orofacial stimulation
Study NCT05282264 — intervention group
Intervention type: OTHER
Intervention: device
Description: closed-loop insulin
Study NCT04696055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg to be administered as an intravenous (IV) infusion every 6 weeks (Q6W).
Study NCT04696055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Regorafenib to be given orally (p.o.) at a starting dose of 90 mg QD for 3 weeks of every 4 weeks (i.e., 3 weeks on, 1 week off). If the starting dose of 90 mg daily is well tolerated the dose should be escalated to 120 mg starting after the first 4-week cycle of regorafenib.
Study NCT05081648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT MuST
Description: Multiple Single Cannulation Technique (MuST): Experimental technique
Study NCT05301686 — intervention group
Intervention type: PROCEDURE
Intervention: Patients with Cyclop lesion
Description: Arthroscopy with resection of Cyclop formation
Study NCT05516888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency of gasserian ganglion
Description: radiofrequency ablation of the gasserian ganglion
Study NCT05516888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency of the peripheral trigeminal branches
Description: radiofrequency of the peripheral trigeminal branches ( maxillary, mandibular, supraorbital)
Study NCT05069519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Smartwatch
Description: Participants will continue with standard care, but will receive a Fitbit and be encouraged to participate in at least 150 min. moderate-to-vigorous physical activity (5 sessions aerobic exercise, 30 min. per session; and 2 sessions of strength training) per week if their body condition allows throughout the intervention period. The previously established daily and weekly exercise prescription will be offered to participants based on their previous week Fitbit data.~PA improvements will be tailored over time based on each participant's previous week PA and they will be encouraged to increase PA by 5-10 min/week if possible depending on specific situations. Participants will save each workout and synchronize the Fitbit PA data to its app where they only share daily data and receive weekly personalized exercise prescriptions established in pilot studies.
Study NCT05081648 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rope-ladder cannulation technique
Description: Standard cannulation technique( Rope-ladder)
Study NCT04834882 — intervention group
Intervention type: OTHER
Intervention: Data collection (
Description: online survey
Study NCT06206668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation videos
Description: The participant will see videos of balance exercises performed by the assigned reference, depending on their group, without performing any physical movement.
Study NCT06206668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Action observation videos
Description: The participant will see videos of balance exercises performed by the assigned reference, depending on their group, without performing any physical movement.
Study NCT06324994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib in combination with Obinutuzumab and Venetoclax
Description: Combined induction period: Linprixate: 80 mg, oral (pre - and post meal), once a day; Otuzumab: 1000 mg/dose, intravenous infusion, administered on the first day (1st cycle is 1, 8, 15 days); (Up to 6 cycles, administration cycle can be adjusted according to clinical treatment conditions); Vineclavone: increase from 40mg, 100mg, and 200mg to 400mg within 4 weeks, followed by a treatment cycle of 400mg orally once a day; (Starting from the third cycle), one cycle every 28 days, for a total of 6 cycles。 Maintenance treatment period: Linprixate: 80 mg, oral (both before and after meals), once a day; Vinecala: 400 mg, oral, once daily; Cycle every 28 days.
Study NCT05069519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook Health Education
Description: Participants assigned to this condition will receive a Fitbit smartwatch, continue with standard care, but will receive health education tips developed in the investigators' previous studies from a private Facebook group in which only group members and researchers can access. Additionally, the investigators will track login counts, analyze their post activity and online sentiments via texting mining and natural language processing, and then offer weekly personalized feedback based on the data to facilitate social support